US EditionTop FDA drug official is trying to hire a friend who’s seeking a bold new warning on antidepressants
FDA's Dr. Tracy Beth Hoeg prioritizes reviewing a petition to add boxed pregnancy warnings on SSRIs amid concerns over fetal risks versus untreated maternal depression.
- The Food and Drug Administration's top drug regulator, Dr. Tracy Beth Hoeg, is trying to hire her friend Dr. Adam Urato, who wants to add new pregnancy warnings to antidepressants.
- Dr. Urato's petition claims antidepressants can cause pregnancy complications like miscarriages and fetal brain abnormalities linked to autism.
- Hoeg is actively working to expedite the FDA's review of Urato's proposal, which outside experts say relies on weak data and could cause pregnant women to stop medication unnecessarily.
64 Articles
64 Articles
The Billings Gazette
Bristol Herald CourierFDA official's friend targets antidepressants
WASHINGTON — The Food and Drug Administration's top drug regulator, Dr. Tracy Beth Hoeg, is working to hire a researcher and friend who wants the agency to add new warnings to antidepressants about unproven pregnancy risks, the Associated Press learned.
Associated Press News
Top FDA drug official is trying to hire a friend who's seeking a bold new warning on antidepressants
The Food and Drug Administration is reviewing a request for new warnings on antidepressant drugs, and that's presenting an unusual conflict of interest at the agency.
The U.S. Food and Drug Administration's (FDA) primary drug regulator, Dr. Tracy Beth Hoeg, works to hire a researcher and friend who wants the agency to add new warnings to antidepressants about unverified risks during pregnancy, according to information obtained by The Associated Press.
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
